cas 121-92-6|| where to buy m-nitrobenzoic acid

Nombre del producto:m-nitrobenzoic acid

IUPAC Name:3-nitrobenzoic acid

Unidad de embalaje	Stock disponible	Precio($)
CM158482-500g	1-2 Weeks	ŉǵǊ
CM158482-1000g	1-2 Weeks	ŉưĽ

Sólo para uso en I+D..

Formulario de consulta

Nombre químico

Número CAS

Cantidad*

Especificaciones requeridas*
(% de ensayo, grado de material, etc.)

Nombre de contacto*

Correo electrónico de contacto*

Meanwhile I'd like to create a registered account on CHEMENU.COM with the above email.

I'd like to receive emails related to products with similar structures to 121-92-6 regularly via the above email.

Notas adicionales

Verification code*

refresh

: Núm. De CAS :121-92-6; Fórmula molecular:C7H5NO4; Punto de fusión:-; Código de sonrisas:O=C(O)C1=CC=CC([N+]([O-])=O)=C1; Densidad:

: Número de catálogo:CM158482; Peso molecular:167.12; Punto de ebullición:; Nº Mdl:MFCD00007251; Almacenamiento:Store at room temperature.

: Benzenes; Benzene is an important organic compound with the chemical formula C6H6, and its molecule consists of a ring of 6 carbon atoms, each with 1 hydrogen atom. Benzene is a sweet, flammable, colorless and transparent liquid with carcinogenic toxicity at room temperature, and has a strong aromatic odor. It is insoluble in water, easily soluble in organic solvents, and can also be used as an organic solvent itself. The ring system of benzene is called benzene ring, and the structure after removing one hydrogen atom from the benzene ring is called phenyl. Benzene is one of the most important basic organic chemical raw materials. Many important chemical intermediates can be derived from benzene through substitution reaction, addition reaction and benzene ring cleavage reaction.

: Tuspetinib; Venetoclax (VEN) combined with a hypomethylating agent (HMA) has proven effective for treating acute myeloid leukemia (AML) patients who are ineligible for intensive chemotherapy. However, this combination therapy still faces issues such as low response rates, limited survival, and potential resistance to VEN.
Aptose’s Tuspetinib (TUS) is a multi-kinase inhibitor selectively targeting SYK, RSK, FLT3 , JAK1/2, KIT, which drive proliferation in AML. The addition of Tuspetinib into VEN and HMA therapy improves medical efficacy and and may help prevent resistance to both agents. TUS+VEN+HMA triplet protocol in frontline therapy for newly diagnosed (ND) AML is currently being tested in a global phase 1/2 trial.